



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 07/12/2010 07:19

Last Report Issued 02/22/2010 13:51

88888

Clinical Dummy reports
Attn: IT Department
200 Welsh Road
Horsham, PA 19044-2208

Patient Name 2395SP-POS

Patient ID 2395SP-POS

Chain 10000432

Age Not Given Gender Not Given

Workorder 10000432

Received 02/22/2010 13:50

Sample ID 10000432-001

Matrix Serum or Plasma

Patient Name 2395SP-POS

Patient ID 2395SP-POS

Container Type Clear vial

Collect Dt/Tm Not Given

Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

2395SP Iloperidone, Serum/Plasma

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Iloperidone 1.0 ng/mL 0.25

Synonym(s): Fanapt®; Fanapta®; Zomaril®

Peak plasma levels of iloperidone are achieved 2 to 4 hours after ingestion. Steady-state concentrations are attained within 3 to 4 days of dosing. The mean plasma level for iloperidone ranges from 2.2 - 2.7 ng/mL following a single 3 mg dose. In one study that examined the pharmacokinetic and pharmacodynamic relationship in regard to iloperidone efficacy, maximal response in terms of therapeutic benefit was observed at plasma concentrations of 5 - 8 ng/mL. Genetic variations may substantially influence the rate of iloperidone metabolism.